**GlaxoSmithKline Capital plc announces the repurchase and cancellation of certain outstanding GBP Notes**

13 February 2023.

GlaxoSmithKline Capital plc (the **Company**) announces today that it has purchased and cancelled the following GBP Notes issued under the Group’s Euro Medium Term Note Programme:

<table>
<thead>
<tr>
<th>Description of the Notes</th>
<th>ISIN / Common Code</th>
<th>Nominal amount of GBP Notes purchased and cancelled</th>
<th>Aggregate Nominal Amount Outstanding after such purchase and cancellations</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.250 per cent. Notes due 19 December 2033</td>
<td>XS0140516864/014051686</td>
<td>£75,783,000</td>
<td>£574,166,000</td>
</tr>
<tr>
<td>6.375 per cent. Notes due 9 March 2039</td>
<td>XS0350820931/035082093</td>
<td>£68,700,000</td>
<td>£631,300,000</td>
</tr>
</tbody>
</table>

**The Company**

GlaxoSmithKline Capital plc
980 Great West Road
Brentford
Middlesex TW8 9GS
United Kingdom

Email: company.secretary@gsk.com

This announcement contains information that qualifies or may qualify as inside information. The person responsible for arranging the release of this announcement on behalf of GlaxoSmithKline Capital plc is Victoria Whyte, Company Secretary.